POMx In the Treatment of Erectile Dysfunction
This study has been completed.
Sponsor:
POM Wonderful LLC
Collaborator:
Target Health Inc.
Information provided by (Responsible Party):
POM Wonderful LLC
ClinicalTrials.gov Identifier:
NCT01220206
First received: October 11, 2010
Last updated: October 4, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
POMx can be used as a treatment for erectile dysfunction.
| Condition | Intervention | Phase |
|---|---|---|
|
Erectile Dysfunction |
Drug: Placebo Drug: One POMx capsule daily Drug: 2 POMx Capsules |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of POM Wonderful Pomegranate Extract Capsules In Male Subjects With Moderate to Severe Erectile Dysfunction |
Resource links provided by NLM:
Further study details as provided by POM Wonderful LLC:
Primary Outcome Measures:
- Effects on ED [ Time Frame: Basedline to end of study ] [ Designated as safety issue: No ]There are three co-primary endpoints: Erectile Function domain score (questions 1-5 and 15 of the IIEF), and questions 2 and 3 on the SEP diary
Secondary Outcome Measures:
- Effect on ED [ Time Frame: baseline to end of study ] [ Designated as safety issue: No ]Secondary efficacy variables are: Total score on SEP and domains of the IIEF representing intercourse satisfaction (questions 6-8), orgasmic function (questions 9-10), and overall satisfaction (questions 11-12) and a Global Assessment Questionnaire.
| Enrollment: | 120 |
| Study Start Date: | August 2011 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
2 placebo capsules daily
|
Drug: Placebo
2 placebo capsules daily
|
|
Experimental: one POMx capsule
One POMx capsule, one placebo capsule daily
|
Drug: One POMx capsule daily
One POMx capsule, one placebo capsule daily
|
|
Experimental: 2 POMx Capsules
2 POMx Capsules daily
|
Drug: 2 POMx Capsules
2 POMx Capsules daily
|
Eligibility| Ages Eligible for Study: | 21 Years to 70 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male 21 to 70 years old
- Erectile Function domain score of 10-19 on the International Index of Erectile Function (IIEF)
- In a stable, monogamous relationship with a consenting female partner and willing to attempt vaginal sexual intercourse on at least one occasion per week on average during each study period
- History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
- Treated previously with a PDE-5 inhibitor with a satisfactory response, as defined by the patient.
- Signed informed consent
Exclusion Criteria:
-The presence of any of the following excludes a subject from study enrollment: ED caused by untreated endocrine disease, i.e., hypopituitarism, hypothyroidism, hypogonadism
- A diagnosis of situational psychogenic ED
- Significant penile pathology, including but not limited to curvature, fibrosis, sexually transmitted disease, and penile implant
- Clinically significant hepatic, renal, neurological disease, diabetes mellitus, spinal cord injury, significant coronary heart disease, significant neurological disease or hepatitis B and/or C
- History of prostate cancer or prostate surgery other than a transurethral resection of the prostate
- History of alcoholism within the previous 2 years
- Current consumer of three or more units of alcohol per day (1 unit is equivalent to 1 glass of wine, 1 pint of beer, or 1 shot of hard liquor)
- Taking ED therapy (prescription medications, over-the-counter medications, herbal preparations or medical devices) after the screening visit
- Participation in another study with an investigational drug or device during the 30 days prior to study entry
- Has a condition interfering with his ability to provide informed consent or comply with study instructions
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01220206
Locations
| United States, Alabama | |
| Medical Affiliated Research Center | |
| Huntsville, Alabama, United States, 35801 | |
Sponsors and Collaborators
POM Wonderful LLC
Target Health Inc.
Investigators
| Principal Investigator: | James McMurray, MD | Medical Affiliated Research Center, Inc. |
More Information
No publications provided
| Responsible Party: | POM Wonderful LLC |
| ClinicalTrials.gov Identifier: | NCT01220206 History of Changes |
| Other Study ID Numbers: | POM 2010-003 |
| Study First Received: | October 11, 2010 |
| Last Updated: | October 4, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by POM Wonderful LLC:
|
ED POMx Pomegranate Erectile dysfunction |
Additional relevant MeSH terms:
|
Erectile Dysfunction Sexual Dysfunction, Physiological Genital Diseases, Male |
Sexual Dysfunctions, Psychological Sexual and Gender Disorders Mental Disorders |
ClinicalTrials.gov processed this record on June 13, 2013